非肌层浸润型膀胱癌TUR-BT术后吉西他滨膀胱热灌注化疗的效果观察  

Effect of gemcitabine bladder hyperthermic perfusion chemotherapy after TUR-BT for non-muscle invasive bladder cancer

作　　者：朱金光 张凯忠[1] ZHU Jin-guang;ZHANG Kai-zhong(First Department of Urology,Maoming People's Hospital,Maoming 525000,Guangdong,CHINA)

机构地区：[1]茂名市人民医院泌尿外一科,广东茂名525000

出　　处：《海南医学》2021年第1期61-64,共4页Hainan Medical Journal

摘　　要：目的探讨非肌层浸润型膀胱癌(NMIBC)患者经尿道膀胱肿瘤电切术(TUR-BT)后吉西他滨膀胱热灌注化疗的应用效果。方法选取2014年6月至2018年6月于茂名市人民医院泌尿外一科接受TUR-BT手术的68例NMIBC患者为研究对象,按照随机单双数法将所有患者分为对照组和观察组,每组34例。对照组患者术后给予表柔比星膀胱灌注化疗,观察组患者术后给予吉西他滨膀胱热灌注化疗,两组患者均治疗6个月。随访1.5年,比较两组患者的复发状况、治疗前、治疗6个月后健康调查简表(SF-36)评分及不良反应发生情况。结果观察组患者的复发率为5.88%,明显低于对照组的26.47%,无复发生存率为94.12%,明显高于对照组的75.53%,差异均有统计学意义(P<0.05);与治疗前比较,治疗6个月后两组患者的SF-36评分均明显提高,且观察组患者的SF-36评分为(81.42±10.46)分,明显高于对照组的(64.35±8.25)分,差异均有统计学意义(P<0.05);观察组患者的不良反应发生率为11.76%,明显低于对照组的35.29%,差异有统计学意义(P<0.05)。结论吉西他滨膀胱热灌注化疗在NMIBC患者TUR-BT术后的应用能有效预防并减少患者术后复发及不良反应发生率,提高其生活质量。Objective To investigate the effect of gemcitabine bladder hyperthermic perfusion chemotherapy after transurethral resection of bladder cancer(TUR-BT)in patients with non-muscle invasive bladder cancer(NMIBC).Methods A total of 68 NMIBC patients,who underwent TUR-BT surgery in First Department of Urology,Maoming People's Hospital from June 2014 to June 2018,were selected as the research subjects.According to random odd-even number method,all the patients were divided into the control group and observation group,with 34 patients in each group.The patients in the control group were given epirubicin bladder perfusion chemotherapy after surgery,and the patients in the observation group were given gemcitabine bladder hyperthermic perfusion chemotherapy after surgery,both for 6 months.After 1.5 years of follow-up,the recurrence status,the health survey summary(SF-36)score before and after treatment,and the adverse reactions status of the two groups were compared.Results The recurrence rate of patients in the observation group was 5.88%,which was significantly lower than 26.47%of the control group(P<0.05);the recurrence-free survival rate was 94.12%,which was significantly higher than 75.53%of the control group(P<0.05).Compared with before surgery,the SF-36 scores of the two groups were significantly improved after 6 months of treatment,and the SF-36 score of the observation group was(81.42±10.46)points,which was significantly higher than(64.35±8.25)points of the control group(P<0.05);the incidence of adverse reactions in the observation group was 11.76%,which was significantly lower than 35.29%of the control group(P<0.05).Conclusion The application of gemcitabine hyperthermic perfusion chemotherapy after TUR-BT can effectively prevent and reduce the incidence of postoperative recurrence and adverse reactions in NMIBC patients and improve their quality of life.

关 键 词：非肌层浸润型膀胱癌 经尿道膀胱肿瘤电切术 膀胱热灌注化疗 吉西他滨 表柔比星 

分 类 号：R737.14[医药卫生—肿瘤]